GSE119603
Differential ncRNAs of oxaliplatin-resistant versus parental HCT116 cells
Oxaliplatin resistance frequently leads to therapeutic failure in colorectal cancer (CRC). Increasing evidence has shown that noncoding RNAs (ncRNAs) play pivotal roles in chemoresistance of CRC. However, the roles and mechanisms of ncRNAs in oxaliplatin resistance are not well understood. In this study, to identify the ncRNAs induced by oxaliplatin, we profile the expression of ncRNAs in oxaliplatin-resistant HCT116 CRC cells (HCT116oxR) and parental HCT116 cells using next-generation sequencing technology. Overall design: CRC cell line HCT116 was purchased from ATCC and cultured as recommended. HCT116 cells were exposed to an initial oxaliplatin concentration of 0.1 µmol/L in RPMI (Roswell Park Memorial Institute) 1640 (Thermo Fisher Scientific, Wilmington, DE, USA) containing 10% FBS (fetal bovine serum) , 100 U/ml penicillin, and 100 g/ml streptomycin. The surviving population of cells was grown to ~80% confluence and passaged twice to ensure viability. The concentration of oxaliplatin that the surviving population was exposed to was then sequentially increased to 0.5 µmol/L, 1.0 µmol/L, 2 µmol/L and finally to the concentration of 5 µmol/L for 1 year. PARALLEL study design with 6 samples, HCT116oxR versus parental HCT116 cell line biological replicates: 3 parental controls, 3 drug resistant, independently grown and harvested. Transcriptome sequencing was performed by next-generation sequencing technology.